SR-9011 POWDER – 1000MG / 1 GRAM

SR-9011: The next-gen metabolic activator igniting the research community

SR-9011 is a second-generation activator of the Rev-ErbA receptors which are found abundantly in liver, skeletal muscle, fat tissue, and the brain.

**LAB USE ONLY**

*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

References

1. L. A. Solt et al., “Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists,” Nature, 2012.
   
2. G. Sulli et al., “Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence,” Nature, 2018.
   
3. H. Duez and B. Staels, “Rev-erbα gives a time cue to metabolism,” FEBS Letters. 2008.
   
4. E. Woldt et al., “Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy,” Nat. Med., 2013.
   
5. S. E. C. Wolff et al., “The Effect of Rev-erbα Agonist SR9011 on the Immune Response and Cell Metabolism of Microglia,” Front. Immunol., 2020.
   
6. D. kai Guo et al., “Pharmacological activation of REV-ERBα represses LPS-induced microglial activation through the NF-κB pathway,” Acta Pharmacol. Sin., 2019.
   
7. A. Mukherji et al., “Shifting eating to the circadian rest phase misaligns the peripheral clocks with the master SCN clock and leads to a metabolic syndrome,” Proc. Natl. Acad. Sci. U. S. A., 2015.
   
8. O. Froy and M. Garaulet, “The circadian clock in white and brown adipose tissue: Mechanistic, endocrine, and clinical aspects,” Endocrine Reviews. 2018.
   
9. S. A. Shea, “Obesity and Pharmacologic Control of the Body Clock,” N. Engl. J. Med., 2012.
   
10. Y. Shin et al., “Small molecule tertiary amines as agonists of the nuclear hormone receptor Rev-erbα,” Bioorganic Med. Chem. Lett., 2012.
    
11. C. J. Morris, D. Aeschbach, and F. A. J. L. Scheer, “Circadian system, sleep and endocrinology,” Molecular and Cellular Endocrinology. 2012.
    
12. T. W. Kim, J. H. Jeong, and S. C. Hong, “The impact of sleep and circadian disturbance on hormones and metabolism,” International Journal of Endocrinology. 2015.
    
13. D. J. Stenvers, F. A. J. L. Scheer, P. Schrauwen, S. E. la Fleur, and A. Kalsbeek, “Circadian clocks and insulin resistance,” Nature Reviews Endocrinology. 2019.
    
14. R. H. Straub and M. Cutolo, “Circadian rhythms in rheumatoid arthritis: Implications for pathophysiology and therapeutic management,” Arthritis and Rheumatism. 2007.
    
15. D. A. Bechtold, J. E. Gibbs, and A. S. I. Loudon, “Circadian dysfunction in disease,” Trends in Pharmacological Sciences. 2010.
    
16. R. Maldonado-Ruiz, L. Montalvo-Martínez, L. Fuentes-Mera, and A. Camacho, “Microglia activation due to obesity programs metabolic failure leading to type two diabetes,” Nutrition and Diabetes. 2017.
    
17. R. Nakazato et al., “The intrinsic microglial clock system regulates interleukin-6 expression,” Glia, 2017.
    
18. E. A. Yu and D. R. Weaver, “Disrupting the circadian clock: Gene-specific effects on aging, cancer, and other phenotypes,” Aging. 2011.
    
19. G. Sulli, E. N. C. Manoogian, P. R. Taub, and S. Panda, “Training the Circadian Clock, Clocking the Drugs, and Drugging the Clock to Prevent, Manage, and Treat Chronic Diseases,” Trends in Pharmacological Sciences. 2018.
    
20. X. Wang, N. Wang, X. Wei, H. Yu, and Z. Wang, “Rev-erbα reduction is associated with clinicopathological features and prognosis in human gastric cancer,” Oncol. Lett., 2018.
    
21. G. Chu, X. Zhou, Y. Hu, S. Shi, and G. Yang, “Rev-erbα inhibits proliferation and promotes apoptosis of preadipocytes through the agonist GSK4112,” Int. J. Mol. Sci., 2019.
    
22. Y. Wang, D. Kojetin, and T. P. Burris, “Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells,” Biochem. Pharmacol., 2015.
    
23. L. Tao et al., “Rev-erbα inhibits proliferation by reducing glycolytic flux and pentose phosphate pathway in human gastric cancer cells,” Oncogenesis, 2019.